Venous Tourniquet vs. Arterial Tourniquet for Seizure Monitoring in ECT

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorMedipol University

About this trial

This prospective, open-label clinical trial aims to compare a novel "Venous Tourniquet with Regional Low-Dose Sugammadex" method against the gold standard "Arterial Tourniquet" (Isolated Forearm Technique - IFT) for monitoring motor seizure activity during Electroconvulsive Therapy (ECT). Using a within-subject (intra-individual) design, each of the 40 enrolled patients will receive an arterial tourniquet on one arm and a venous tourniquet on the other arm simultaneously. The study will evaluate clinical efficacy in observing motor seizures, comparing the duration and visibility between the two limbs of the same patient, as well as assessing overall patient comfort and hemodynamics.

Eligibility criteria

Qualifiers

Patients scheduled for elective Electroconvulsive Therapy (ECT).

ASA (American Society of Anesthesiologists) physical status I to III.

Disqualifiers

Known neuromuscular diseases (e.g., Myasthenia Gravis).

Known allergy or hypersensitivity to sugammadex, rocuronium, ketamine, dexmedetomidine, or propofol.

Presence of venous insufficiency, lymphedema, or active infection in the upper extremities.

Severe cardiovascular instability.

Trial design

Treatments tested in this trial

  • Device: Arterial Tourniquet
  • Device: Venous Tourniquet
  • Sugammadex

Treatment groups

20 Participants
are divided into 1 treatment group

Sponsors and collaborators